Brief: Island Pharmaceuticals Says IND To U.S. FDA For Phase 2A Peach Clinical Trial
28/12/2022 24:03
Dec 28 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* IND TO US FDA FOR PHASE 2A PEACH CLINICAL TRIAL
Source text for Eikon: ID:nASX8JDjP8
Further company coverage: ILA.AX
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic